Clinical and Translational Oncology

, Volume 15, Issue 5, pp 370–375 | Cite as

Clinical report on transarterial neoadjuvant chemotherapy of malignant fibrous histiocytoma in soft tissue

  • Jun Guo
  • Qiu Cui
  • Cheng Liu
  • Jiahong Sui
  • Ning Jiang
  • Ju Zhou
  • Dingfeng Li
  • Yanjun Zeng
Research Article

Abstract

Purpose

To review the experience in transarterial neoadjuvant chemotherapy of malignant fibrous histiocytoma (MFH) in soft tissue and to analyze the factors related to prognosis of MFH in soft tissue.

Methods

Between September 1999 and December 2011, 101 cases of MFH in soft tissue patients treated by transarterial administration of Cisplatin, Adriamycin and Norcantharidin were divided into primary group and recurrent group, and the clinical documents were reviewed. Nine factors that might affect prognosis such as age, sex, tumor size, tumor site, tumor infiltration depth, recurrence if any, pathological type, histologic grade and histologic response of chemotherapy were analyzed statistically.

Results

The 5-year relapse-free survival rate and the overall survival rate were 70.5 and 75.0 %, respectively, in the primary group; 56.1 and 57.9 %, respectively, in the recurrent group. Univariate analysis (log-rank test) showed that the factors affecting the prognosis were age (P = 0.03), tumor size (P = 0.01), pelvic tumor (P = 0.02), recurrence if any (P = 0.004), histologic grade (P = 0.01), and histologic response to chemotherapy (P = 0.007). Multivariate analysis showed that the major factors affecting prognosis were pelvic tumor (P = 0.01), tumor size (P = 0.002), histologic grade (P = 0.002), recurrence if any (P = 0.0004), and histologic response to chemotherapy (P = 0.008).

Conclusion

Transarterial neoadjuvant chemotherapy can significantly increase the curative efficacy of chemotherapy and survival rate in MFH treatment.

Keywords

Malignant fibrous histiocytoma Soft tissue Transarterial neoadjuvant chemotherapy Prognosis 

References

  1. 1.
    O’Brien JE, Stout AP (1964) Malignant fibrous xanthomas. Cancer 11:1445–1455CrossRefGoogle Scholar
  2. 2.
    Fletcher CDM, Unni KK, Mertens F (eds) (2002) Pathology and genetics of tumours of soft tissues and bone. World Health Organization classification of tumors. IARC Press, LyonGoogle Scholar
  3. 3.
    Enzinger FM, Weiss SW (2001) Soft tissue tumors, 4th edn. Mosby, St. LouisGoogle Scholar
  4. 4.
    Peiper M, Zurakowski D, Knoefel WT, Izbicki JR (2004) Malignant fibrous histiocytoma of the extremities and trunk: an institutional review. Surgery 135(1):59–66PubMedCrossRefGoogle Scholar
  5. 5.
    Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230PubMedCrossRefGoogle Scholar
  6. 6.
    Lehnhardt M, Daigeler A, Homann HH, Schwaiberger V, Goertz O, Kuhnen C, Steinau HU (2009) MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities—an analysis of 140 patients. Langenbecks Arch Surg 394:313–320PubMedCrossRefGoogle Scholar
  7. 7.
    Belal A, Kandil A, Allam A, Khafaga Y, El-Husseiny G, El-Enbaby A, Memon M, Younge D, Moreau P, Gray A, Schultz H (2002) Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol 25(1):16–22PubMedCrossRefGoogle Scholar
  8. 8.
    Guang-xue LI, Wei GUO (2011) Analysis of therapeutic strategies and prognostic factors of malignant fibrous histiocytoma of soft tissue. Chin J Surg 49(11):974–977Google Scholar
  9. 9.
    Gibbs JF, Huang PP, Lee RJ, McGrath B, Brooks J, McKinley B, Driscoll D, Kraybill WG (2001) Malignant fibrous histiocytoma: an institutional review. Cancer Invest 19(1):23–27PubMedCrossRefGoogle Scholar
  10. 10.
    Bacci G, Ferrari S, Picci P et al (1996) Neoadjuvant chemotherapy in malignant fibrous histiocytoma of the limbs: 10 years of experience (1983–1992) at the Rizzoli Orthopedic Institute. Minerva Med 87(4):135–146PubMedGoogle Scholar
  11. 11.
    Atalar H, Başarir K, Yildiz Y, Sağlik Y (2007) Prognostic factors in patients with malignant fibrous histiocytoma of the extremities. Acta Orthop Traumatol Turc 41(4):271–276PubMedGoogle Scholar
  12. 12.
    Hugate RR, Wilkins RM, Cynthia M et al (2008) Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults. Clin Orthop Relat Res 6(466):1292–1301CrossRefGoogle Scholar
  13. 13.
    Gutierrez JC, Perez EA, Franceschi D, Moffat FL Jr, Livingstone AS, Koniaris LG (2007) Outcomes for soft-tissue sarcoma in 8,249 cases from a large state cancer registry. J Sung Res 141(1):105–114CrossRefGoogle Scholar
  14. 14.
    Ham SJ, Hoekstra HJ, van der Graaf WT, Kamps WA, Molenaar WM, Schraffordt Koops H (1996) The value of high-dose methotrexate-based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone. J Clin Oncol 14(2):490–496PubMedGoogle Scholar
  15. 15.
    Bacci G, Springfield D, Capanna R, Picci P, Bertoni F, Campanacci M (1985) Adjuvant chemotherapy for malignant fibrous histiocytoma in the femur and tibia. J Bone Joint Surg [Am] 67:620–625Google Scholar
  16. 16.
    Picci P, Bacci G, Ferrari S, Mercuri M (1997) Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. Ann Oncol 8(11):1107–1115PubMedCrossRefGoogle Scholar
  17. 17.
    Nooij MA, Whelan J, Bramwell VH, Taminiau AT, Cannon S, Hogendoorn PC, Pringle J, Uscinska BM, Weeden S, Kirkpatrick A, Glabbeke M, European Osteosarcoma Intergroup (2005) Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer 41(2):225–230PubMedCrossRefGoogle Scholar
  18. 18.
    Bramwell VH, Steward WP, Nooij M, Whelan J, Craft AW, Grimer RJ, Taminau AH, Cannon SR, Malcolm AJ, Hogendoorn PC, Uscinska B, Kirkpatrick AL, Machin D, Van Glabbeke MM (1999) Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study. J Clin Oncol 17(10):3260–3269PubMedGoogle Scholar
  19. 19.
    Shiba M, Takatera H, Fujii T, Tokizane T, Shimizu K, Tushima J (2004) Intraarterial chemotherapy with bladder preservation in patients with invasive bladder carcinoma. Hinyokika Kiyo 50(1):15–19PubMedGoogle Scholar
  20. 20.
    Bacci G, Ruggieri P, Picci P, Mercuri M, Ferraro A, Tella G, Ferrari S, Bertoni F, Comandone A (1996) Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study. J Chemother 8(1):70–81PubMedGoogle Scholar
  21. 21.
    Yang PY, Chen MF, Kao YH, Hu DN, Chang FR, Wu YC (2011) Norcantharidin induces apoptosis of breast cancer cells: involvement of activities of mitogen activated protein kinases and signal transducers and activators of transcription. Toxicol In Vitro 25(3):699–707PubMedCrossRefGoogle Scholar
  22. 22.
    Mack P, Ha XF, Cheng LY (1996) Efficacy of intra-arterial norcantharidin in suppressing tumour 14C-labelled glucose oxidative metabolism in rat Morris Hepatoma. HPB Surg 10(2):65–72PubMedCrossRefGoogle Scholar
  23. 23.
    Salo JC, Lewis JJ, Woodruff JM, Leung DH, Brennan MF (1999) Malignant fibrous histiocytoma of the extremity. Cancer 85:1765–1772PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2012

Authors and Affiliations

  • Jun Guo
    • 1
  • Qiu Cui
    • 1
  • Cheng Liu
    • 1
  • Jiahong Sui
    • 1
  • Ning Jiang
    • 1
  • Ju Zhou
    • 1
  • Dingfeng Li
    • 1
  • Yanjun Zeng
    • 2
  1. 1.Department of Orthopedics307 Hospital of PLABeijingChina
  2. 2.Biomedical Engineering Center, Beijing University of TechnologyBeijingChina

Personalised recommendations